GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » Cash Ratio

Oncimmune Holdings (LSE:ONC) Cash Ratio : 0.32 (As of Feb. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Oncimmune Holdings's Cash Ratio for the quarter that ended in Feb. 2024 was 0.32.

Oncimmune Holdings has a Cash Ratio of 0.32. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Oncimmune Holdings's Cash Ratio or its related term are showing as below:

LSE:ONC' s Cash Ratio Range Over the Past 10 Years
Min: 0.11   Med: 1.78   Max: 15.26
Current: 0.32

During the past 12 years, Oncimmune Holdings's highest Cash Ratio was 15.26. The lowest was 0.11. And the median was 1.78.

LSE:ONC's Cash Ratio is ranked worse than
86.54% of 1508 companies
in the Biotechnology industry
Industry Median: 2.955 vs LSE:ONC: 0.32

Oncimmune Holdings Cash Ratio Historical Data

The historical data trend for Oncimmune Holdings's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings Cash Ratio Chart

Oncimmune Holdings Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 Aug23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.05 1.22 1.78 0.17 2.26

Oncimmune Holdings Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Feb23 Aug23 Feb24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.17 0.11 2.26 0.32

Competitive Comparison of Oncimmune Holdings's Cash Ratio

For the Biotechnology subindustry, Oncimmune Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncimmune Holdings's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's Cash Ratio falls into.



Oncimmune Holdings Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Oncimmune Holdings's Cash Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash Ratio (A: Aug. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3.209/1.422
=2.26

Oncimmune Holdings's Cash Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash Ratio (Q: Feb. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.911/2.85
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncimmune Holdings  (LSE:ONC) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Oncimmune Holdings Cash Ratio Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncimmune Holdings (LSE:ONC) Business Description

Traded in Other Exchanges
Address
1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.

Oncimmune Holdings (LSE:ONC) Headlines

No Headlines